Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31498434 | 1.00 | KDM4E (0.47) | KDM4EMAPK1TDP1FBP1MAPT | |
| SCHEMBL24150735 | 0.96 | KDM4E (0.49) | KDM4EMAPK1TDP1FBP1MAPT | |
| SCHEMBL12745131 | 0.95 | KDM4E (0.56) | KDM4EMAPK1TDP1FBP1MAPT | |
| SCHEMBL31498483 | 0.95 | KDM4E (0.56) | KDM4EMAPK1TDP1FBP1MAPT | |
| SCHEMBL30334792 | 0.83 | CA12 (0.50) | KDM4EMAPK1TDP1MAPTLMNA | |
| SCHEMBL29843581 | 0.83 | LMNA (0.45) | KDM4EMAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL5829630 | 0.83 | LMNA (0.45) | KDM4EMAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL4057003 | 0.83 | CA12 (0.50) | KDM4EMAPK1TDP1MAPTSMN1; SMN2 | |
| SCHEMBL1608519 | 0.83 | CA12 (0.50) | KDM4EMAPK1TDP1MAPTLMNA | |
| SCHEMBL14930516 | 0.82 | CYP1A2 (0.54) | KDM4EMAPK1TDP1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7045522-B2 | 8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives technical field | NEUROSEARCH A/S (DK) | 2006-05-16 | — | — | US | disclosed |
| CN-1231483-C | 8-azabicyclo [3.2.1] oct-2-ene and-octane derivatives | NEUROSEARCH AS (DK) | 2005-12-14 | — | — | CN | disclosed |
| US-20040116703-A1 | 8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives technical field | NEUROSEARCH A/S | 2004-06-17 | — | — | US | disclosed |
| EP-1133494-B1 | 8-AZABICYCLO 3.2.1]OCT-2-ENE AND -OCTANE DERIVATIVES | NEUROSEARCH AS (DK) | 2004-02-18 | — | — | EP | disclosed |
| EP-1382605-A2 | 8-azabicyclo(3.2.1)oct-2-ene derivatives and their use as nAChR ligands | NEUROSEARCH A/S (DK) | 2004-01-21 | — | — | EP | disclosed |
| US-6680328-B2 | CHOLINERGIC LIGANDS OF NICOTINIC ACETYL CHOLINE RECEPTORS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, SMOOTH MUSCLE CONTRACTION DISORDERS, ENDOCRINE DISEASES/DISORDERS, NEURODEGENERATION, INFLAMMATION, PAIN, AND DRUG WITHDRAWAL | NEUROSEARCH A/S (DK) | 2004-01-20 | — | — | US | disclosed |
| US-20020035122-A1 | 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives | ANIONA APS (DK) | 2002-03-21 | — | — | US | disclosed |
| CN-1326456-A | 8-azabicyclo [3,.2.1] oct-2-ene and-octane derivatives | NEUROSEARCH AS (DK) | 2001-12-12 | — | — | CN | disclosed |
| EP-1133494-A1 | 8-AZABICYCLO 3.2.1]OCT-2-ENE AND -OCTANE DERIVATIVES | NEUROSEARCH A/S (DK) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000032600-A1 | 8-AZABICYCLO[3.2.1]OCT-2-ENE AND -OCTANE DERIVATIVES | NEUROSEARCH A/S (DK) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035122-A1 | 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives | CHRNA2, CHRNA7, CHRNA10 | KDM4E 631/4885MAPK1 1026/4885TDP1 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.